← Esperion Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $148.4m |
$227.5m
+53.37%
|
$78.4m
-65.52%
|
$75.5m
-3.79%
|
$116.3m
+54.14%
|
$332.3m
+185.66%
|
$403.1m
+21.31%
|
$418.2m
+3.75%
|
|
| Cost of goods sold | $57.9m | $147.6m | $0 | $0 | $2.4m |
$14.2m
+494.36%
|
$27.0m
+89.68%
|
$43.3m
+60.44%
|
$68.6m
+58.55%
|
$129.2m |
$132.3m
+2.35%
|
|
| Gross Profit (derived) | ($57.9m) |
($147.6m)
-155.07%
|
$0
+100.00%
|
$148.4m |
$225.2m
+51.76%
|
$64.2m
-71.47%
|
$48.5m
-24.48%
|
$73.1m
+50.63%
|
$263.7m
+260.92%
|
$273.9m
+3.87%
|
$286.0m
+4.41%
|
|
| Research and development | $57.9m | $147.6m | $171.5m | $175.6m | $146.9m | $106.0m | $118.9m | $86.1m | $46.2m | $47.9m | $44.3m | |
| Selling, general and administrative | $18.3m | $21.4m | $33.1m | $65.9m | $199.6m | $185.0m | $109.1m | $142.5m | $163.1m | $165.8m | $165.9m | |
| Operating Costs and Expenses | — | — | — | — | — | — | — | — | — | $129.2m | — | |
| Total operating expenses | $76.2m | $169.0m | $204.6m | $241.5m | $348.9m | $305.2m | $255.0m | $271.9m | $277.9m | $342.9m | $342.5m | |
| Operating Income (Loss) | ($76.2m) |
($169.0m)
-121.91%
|
($204.6m)
-21.07%
|
($93.1m)
+54.49%
|
($121.4m)
-30.39%
|
($226.7m)
-86.77%
|
($179.5m)
+20.83%
|
($155.6m)
+13.34%
|
$54.4m
+134.97%
|
$60.3m
+10.79%
|
$75.8m
+25.74%
|
|
| Interest expense | ($376k) | ($198k) | ($28k) | ($8.1m) | ($22.7m) | ($46.4m) | ($56.8m) | ($59.0m) | ($59.3m) | ($84.6m) | $85.0m | |
| Other income, net | $1.5m | $2.2m | $2.8m | $4.1m | $515k | $4.0m | $2.7m | $5.3m | $8.0m | $3.5m | $3.6m | |
| Other Nonoperating Income (Expense) | $1.5m | $2.2m | $2.8m | $4.1m | $515k | $4.0m | $2.7m | $5.3m | $8.0m | $3.5m | — | |
| Loss before income taxes | — | — | — | — | — | — | — | ($209.2m) | ($51.7m) | ($20.8m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $76.2m | $169.0m | $204.6m | $93.1m | $121.4m | $226.7m | $179.5m | $155.6m | $54.4m | ($20.8m) | ($5.6m) | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $1.8m | $1.8m | |
| Net loss | ($75.0m) | ($167.0m) | ($201.8m) |
($97.2m)
+51.85%
|
($143.6m) | ($269.1m) | ($233.7m) | ($209.2m) | ($51.7m) | ($22.7m) | — | |
| Net loss per common share - basic (in dollars per share) | ($3) | ($7) | ($8) | ($4) | ($5) | ($9) | ($4) | ($2) | ($0) | ($0) | — | |
| Net loss per common share - diluted (in dollars per share) | ($3) | ($7) | ($8) | ($4) | ($5) | ($9) | ($4) | ($2) | ($0) | ($0) | — | |
| Net Income (Loss) Attributable to Parent | ($75.0m) |
($167.0m)
-122.72%
|
($201.8m)
-20.85%
|
($97.2m)
+51.85%
|
($143.6m)
-47.74%
|
($269.1m)
-87.47%
|
($233.7m)
+13.17%
|
($209.2m)
+10.45%
|
($51.7m)
+75.27%
|
($22.7m)
+56.17%
|
($7.4m)
+67.27%
|
|
| Earnings Per Share, Basic | ($3) | ($7) | ($8) | ($3.59) | ($5.23) | ($9.31) | ($3.52) | ($2.03) | ($0.28) | ($0.11) | $0.00 | |
| Earnings Per Share, Diluted | ($3.33) | ($6.98) | ($7.54) | ($3.59) | ($5.23) | ($9.31) | ($3.52) | ($2.03) | ($0.28) | ($0.11) | $0.00 | |
| Weighted-average shares outstanding - basic (in shares) | — | — | — | 27.1m | 27.5m | 28.9m | 66.4m | 103.1m | 187.2m | 207.9m | — | |
| Weighted-average shares outstanding - diluted (in shares) | — | — | — | 27.1m | 27.5m | 28.9m | 66.4m | 103.1m | 187.2m | 207.9m | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 27.1m | 27.5m | 28.9m | 66.4m | 103.1m | 187.2m | 207.9m | 221.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 27.1m | 27.5m | 28.9m | 66.4m | 103.1m | 187.2m | 207.9m | 221.7m | |
| Income (loss) from operations | ($76.2m) |
($169.0m)
-121.91%
|
($204.6m)
-21.07%
|
($93.1m)
+54.49%
|
($121.4m)
-30.39%
|
($226.7m)
-86.77%
|
($179.5m)
+20.83%
|
($155.6m)
+13.34%
|
$54.4m
+134.97%
|
$60.3m
+10.79%
|
$75.8m
+25.74%
|
|
| Loss on extinguishment of debt and exchange transaction | — | — | — | — | — | — | $0 | $0 | ($54.9m) | $0 | — | |
| Provision for taxes on income | — | — | — | — | — | — | — | $0 | $0 | $1.8m | — | |
| Unrealized gain on investments | $310k | ($673k) | $526k | $342k | ($23k) | ($31k) | $29k | $2k | $0 | $0 | — | |
| Other Cost and Expense, Operating | $57.9m | $147.6m | $0 | $0 | $2.4m | $14.2m | $27.0m | $43.3m | $68.6m | $129.2m | — | |
| Total comprehensive loss | ($74.7m) | ($167.7m) | ($201.3m) | ($96.8m) | ($143.6m) | ($269.1m) | ($233.6m) | ($209.2m) | ($51.7m) | ($22.7m) | — |